143979-40-2

Basic information

• Product Name: rac N-Boc-3,3-dimethyl-2-pyrrolidenecarboxylic Acid
• Synonyms: 3,3-Dimethyl-1,2-pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester;rac N-Boc-3,3-dimethyl-2-pyrrolidenecarboxylic Acid;(R,S)-Boc-3,3-dimethyl-proline;1-[(Tert-butyl)oxycarbonyl]-3,3-diMethylpyrrolidine-2-carboxylic acid;(R,S)-Boc-3,3-diMethyl-pyrrolidine-2-carboxylic acid;1,2-Pyrrolidinedicarboxylic acid, 3,3-diMethyl-, 1-(1,1-diMethylethyl) ester;Boc-3,3-dimethyl-proline;1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidine-2-carboxylic acid
• CAS NO: 143979-40-2
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Product Categories: Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives;Heterocycles
• Mol File: 143979-40-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 345.1°C at 760 mmHg
• Flash Point: 162.5°C
• Appearance: /
• Density: 1.117g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.483
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Ethyl Acetate, Methanol (Slightly)
• PKA: 4.04±0.40(Predicted)
• CAS DataBase Reference: rac N-Boc-3,3-dimethyl-2-pyrrolidenecarboxylic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: rac N-Boc-3,3-dimethyl-2-pyrrolidenecarboxylic Acid(143979-40-2)
• EPA Substance Registry System: rac N-Boc-3,3-dimethyl-2-pyrrolidenecarboxylic Acid(143979-40-2)

Safety Data

• Hazardous Substances Data: 143979-40-2(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C12H21NO4/c1-11(2,3)17-10(16)13-7-6-12(4,5)8(13)9(14)15/h8H,6-7H2,1-5H3,(H,14,15)

Upstream product

• 61406-78-8 3,3-dimethylproline hydrochloric acid salt 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

Protected amino hydroxy adamantane carboxylic acid and process for its preparation

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided. The provided compounds can be used for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.